Incyte Corporation
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- William J. Meury
- Full Time Employees
- 2,617
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1801 Augustine Cut-Off Wilmington DE United States of America 19803
- IPO Date
- Nov 4, 1993
- CIK
- 0000879169
- Website
- incyte.com
- Similar Companies
- Business
- Incyte Corporation (INCY) is a Wilmington, Delaware-based biopharmaceutical company founded in 2002 that discovers, develops, and commercializes proprietary medicines for oncology, inflammation, autoimmunity, and dermatology; it operates globally in North America, Europe, and Asia with over 2,500 employees focused on unmet medical needs. The company markets a diversified portfolio of approved products including Jakafi (ruxolitinib) for myelofibrosis, polycythemia vera, and graft-versus-host disease; Opzelura (ruxolitinib) cream for atopic dermatitis and vitiligo; Pemazyre (pemigatinib) for cholangiocarcinoma and myeloid/lymphoid neoplasms; Monjuvi (tafasitamab-cxix) for relapsed or refractory diffuse large B-cell lymphoma; Tabrecta (capmatinib) for non-small cell lung cancer; Iclusig (ponatinib) for leukemia; and Olumiant (baricitinib) for rheumatoid arthritis and alopecia areata; it also advances a robust pipeline of clinical candidates discovered in-house targeting immunology, hematology-oncology, and inflammatory skin conditions. Recent developments include the 2024 acquisition of Escient Pharmaceuticals for $750 million to add first-in-class oral MRGPRX2 antagonists EP262 for hidradenitis suppurativa, prurigo nodularis, and other pruritic skin diseases and EP547 for pruritus in kidney and liver diseases; FDA approval of Niktimvo (axatilimab-csfr) with partner Syndax Pharmaceuticals in August 2024 for chronic graft-versus-host disease; relocation of over 300 Pennsylvania jobs to expanded downtown Wilmington headquarters by 2026 supporting more than 500 positions; and a 2025 roadmap featuring four potential product launches such as ruxolitinib XR and povorcitinib expansions, four pivotal trial readouts, seven proof-of-concept disclosures, and at least three Phase 3 initiations toward over 10 high-impact launches by 2030.
Here Are Monday's Best Wall Street Analyst Research Calls: Accenture, Apple, Boyd Gaming, BWX Technologies, Conoco-Phillips, Estee Lauder, Hut 8, Incyte, SpaceX, and More
Why Incyte (INCY) is a Top Momentum Stock for the Long-Term
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essenti
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progr
Incyte Nears Buy Point As $1.25 Billion Acquisition Expands Offerings
Here's Why Incyte (INCY) is a Strong Value Stock
Chip Weakness, Middle East Concerns Drag Dow 549 Points
Incyte: I Am Moving From Hold To Buy
Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2B
Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential
Incyte Corporation (INCY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Incyte Corporation (INCY) M&A Call Transcript